Acute Myeloid Leukemia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Acute Myeloid Leukemia stocks.

Acute Myeloid Leukemia Stocks Recent News

Date Stock Title
Mar 28 BEAM Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Mar 28 APLM Apollomics GAAP EPS of -$2.32
Mar 28 ACLX Insiders Are Dumping These 10 Healthcare Stocks
Mar 28 APLM Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
Mar 27 BLRX BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript
Mar 27 APTO Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript
Mar 27 BLRX BLRX: First Aphexda Sales Recognized
Mar 27 ACLX Insider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares
Mar 27 APTO Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript
Mar 26 APTO Aptose Biosciences GAAP EPS of -$7.58 beats by $0.40
Mar 26 APTO Aptose Reports Results for the Fourth Quarter and Full Year 2023
Mar 26 BLRX BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript
Mar 26 APLM Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
Mar 26 ATNM Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Mar 26 BLRX BioLineRx GAAP EPS of -$0.06, revenue of $4.8M
Mar 26 BLRX BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
Mar 26 BEAM Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Mar 25 APTO Aptose Biosciences Q4 2023 Earnings Preview
Mar 25 BLRX biolinerx Q4 2023 Earnings Preview
Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cells. Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally spread may occur to the brain, skin, or gums. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.Risk factors include smoking, previous chemotherapy or radiation therapy, myelodysplastic syndrome, and exposure to the chemical benzene. The underlying mechanism involves replacement of normal bone marrow with leukemia cells, which results in a drop in red blood cells, platelets, and normal white blood cells. Diagnosis is generally based on bone marrow aspiration and specific blood tests. AML has several subtypes; for which treatments and outcomes may vary.AML, typically is initially treated with chemotherapy aimed at inducing remission. People may then go on to receive additional chemotherapy, radiation therapy, or a stem cell transplant. The specific genetic mutations present within the cancer cells may guide therapy, as well as determine how long that person is likely to survive. Arsenic trioxide may be tried in cases that have recurred following usual treatments.AML affected about one million people globally in 2015 and resulted in 147,000 deaths. It most commonly occurs in older adults. Males are affected more often than females. AML is curable in about 35% of people under 60 years old and 10% over 60 years old. Older people who are not healthy enough to receive intensive chemotherapy have a typical survival of 5–10 months. It accounts for roughly 1.8% of cancer deaths in the United States.

Browse All Tags